XCancer

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Description:

The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.

Sponsor:

Peking University Cancer Hospital & Institute

Phase:

N/A

Contacts:

Hua Zhu (CONTACT)

zhuhuabch@pku.edu.cn

010-88196495

Hua Zhu (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT05436093 - Click here to see study on

ClinicalTrials.gov

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

ACN376

Isotope(s):
Target(s):
  • Claudin 18.2
Ligand Class: Small Proteins and Antibody Fragments
Inclusion
  • * 1\. Aged \>18 years old; ECOG 0 or 1;
  • 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
  • 4\. life expectancy \>=12 weeks.
  • 2\. Patients with solid tumors;
Exclusion
  • * 1\. Significant hepatic or renal dysfunction;
  • 5\. Suffering from claustrophobia or other mental diseases;
  • 4\. Refusal to join the clinical study;
  • 2\. Is pregnant or ready to pregnant;
  • 3\. Cannot keep their states for half an hour;